Cognition Therapeutics Inc (CGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $64.65M
Last updated: Nov 17, 2026 at 11:03 AM ET
Cognition Therapeutics Inc (CGTX) Earnings: Report Dates and Results
Cognition Therapeutics (CGTX) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Cognition Therapeutics reported EPS of -$0.04, above the -$0.07 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CGTX has an expected report date of Mar 24, 2027.
CGTX Earnings Call
The latest CGTX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, CGTX beat 15 and missed 6. The widest gap in the table came in the quarter ended Jun 30, 2021, when EPS landed 176.19% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.04 | -$0.07 | -$0.07 - -$0.06 | +42.86% | Beat | N/A | 3 | 1 up, 0 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.04 | -$0.06 | -$0.07 - -$0.06 | +33.33% | Beat | N/A | 3 | 2 up, 1 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.05 | -$0.07 | -$0.10 - -$0.02 | +28.57% | Beat | N/A | 4 | 1 up, 1 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.02 | -$0.08 | -$0.13 - -$0.05 | +74.19% | Beat | N/A | 4 | 1 up, 1 down | Mar 26, 2026 | N/A |
| Sep 30, 2025 | -$0.06 | -$0.11 | -$0.14 - -$0.06 | +45.45% | Beat | N/A | 4 | 3 up, 1 down | Nov 6, 2025 | N/A |
| Jun 30, 2025 | -$0.11 | -$0.12 | -$0.14 - -$0.06 | +8.33% | Beat | N/A | 4 | 1 up, 2 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$0.14 | -$0.11 | -$0.14 - -$0.09 | -27.27% | Miss | N/A | 4 | 2 up, 1 down | May 7, 2025 | N/A |
| Dec 31, 2024 | -$0.19 | -$0.17 | -$0.21 - -$0.07 | -11.00% | Miss | N/A | 4 | 1 up, 1 down | Mar 20, 2025 | $250000 |
| Sep 30, 2024 | -$0.25 | -$0.21 | -$0.31 - -$0.16 | -19.05% | Miss | N/A | 4 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.18 | -$0.23 | -$0.28 - -$0.14 | +21.74% | Beat | N/A | 6 | 0 up, 1 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.27 | -$0.24 | -$0.26 - -$0.23 | -12.50% | Miss | N/A | 3 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.27 | -$0.34 | -$0.40 - -$0.27 | +20.59% | Beat | N/A | 3 | 0 up, 0 down | Mar 26, 2024 | $372000 |
| Sep 30, 2023 | -$0.22 | -$0.29 | -$0.36 - -$0.08 | +24.14% | Beat | N/A | 4 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$0.16 | -$0.21 | -$0.34 - -$0.12 | +23.81% | Beat | N/A | 4 | 0 up, 0 down | Aug 8, 2023 | N/A |
| Mar 31, 2023 | -$0.21 | -$0.18 | -$0.18 - -$0.17 | -16.67% | Miss | N/A | 3 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$0.20 | -$0.30 | -$0.49 - $0.15 | +33.33% | Beat | N/A | 4 | 0 up, 0 down | Mar 23, 2023 | N/A |
| Sep 30, 2022 | -$0.29 | -$0.32 | -$0.55 - -$0.28 | +9.38% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$0.25 | -$0.32 | -$0.42 - -$0.20 | +21.88% | Beat | N/A | 3 | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$0.17 | -$0.29 | -$0.38 - -$0.16 | +41.38% | Beat | N/A | 3 | 0 up, 0 down | May 11, 2022 | N/A |
| Dec 31, 2021 | -$11.74 | -$0.26 | -$0.35 - -$0.17 | N/A | N/A | N/A | 2 | 0 up, 0 down | Mar 30, 2022 | $6.92M |
| Sep 30, 2021 | -$0.18 | -$0.57 | -$0.57 - -$0.57 | +68.42% | Beat | N/A | 1 | N/A | Oct 8, 2021 | N/A |
| Jun 30, 2021 | -$0.58 | -$0.21 | N/A | -176.19% | Miss | N/A | N/A | N/A | Jul 19, 2021 | $3.60M |
| Mar 31, 2021 | -$4.77 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | $4.69M |
| Dec 31, 2020 | -$1.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | N/A |
| Mar 31, 2020 | -$5.59 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | -$7.58 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.33, after -$0.89 the year before. It was -$7.58 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.33 | N/A |
| Dec 31, 2024 | -$0.89 | N/A |
| Dec 31, 2023 | -$0.86 | N/A |
| Dec 31, 2022 | -$0.91 | N/A |
| Dec 31, 2021 | -$17.27 | N/A |
| Dec 31, 2020 | -$7.24 | N/A |
| Dec 31, 2019 | -$7.58 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,200 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,195 | 7 | |
| 2024Q4 | Dec 31, 2024 | 3,091 | 8 |
2026Q3 Earnings Call
Opening remarks
Mike Moyer Managing Director, LifeSci Advisors Thank you, operator. Good morning, everyone. Welcome to Cognition Therapeutics' Third Quarter 2026 Conference Call. With me today are Lisa Ricciardi, President and Chief Executive Officer; John Doyle, Chief Financial Officer; and Dr. Tony Caggiano, Chief Medical Officer. This morning, the company issued a press release detailing its financial results for the quarter. We encourage everyone to read this morning's press release, as well as Cognition's Form 10-Q, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to the risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Cognition's press releases and SEC filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Cognition undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I would now like to turn the call over to Lisa Ricciardi.
Lisa Ricciardi President and Chief Executive Officer Mike, thank you, and good morning, everyone. As you can see on the agenda, the first topic we'd like to cover on this call is the registrational plan for zervimesine, or CT1812, in the treatment of people with dementia with Lewy bodies, which we'll refer to in this call as DLB. Two weeks ago, we announced that we reached alignment with the FDA on a planned registrational trial for zervimesine in people living with DLB. Investors who have been following Cognition are aware that this topic has been the subject of several meetings with the FDA. We conducted meetings in January, May, and October, and all along, we've encountered FDA staff at every step who are engaged and constructive. As a result of our interactions, Cognition Therapeutics is the first company to align on a phase III trial with the FDA for this class of drugs to treat DLB. Other companies have designed phase III trials for symptomatic treatment, such as antipsychotics or medications for agitation in this population. Zervimesine is unique in that it is designed to slow the course of the disease, not just treat the symptoms. I am proud that we have tackled an uncharted development path together with the FDA. Now, we are working to complete a protocol for zervimesine's phase III program.
Frequently Asked Questions About CGTX
When is Cognition Therapeutics's next earnings date?
Cognition Therapeutics's next earnings report is expected for Mar 24, 2027.
Did CGTX beat earnings estimates last quarter?
Yes. Cognition Therapeutics reported EPS of -$0.04 for the quarter ended Sep 30, 2026, above the -$0.07 estimate, a 42.86% surprise.
What EPS do analysts expect from CGTX next quarter?
The consensus EPS estimate for Cognition Therapeutics for the quarter ending Dec 31, 2026 is -$0.14 from 5 analysts, with estimates from -$0.25 to -$0.05.
How often does CGTX beat earnings estimates?
Cognition Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +24.31%.
CGTX pages: Overview, Earnings, Forecast, Financials, Competitors